2-(三氟甲基)苯-1-硫代苯甲酰胺 | 886496-67-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(三氟甲基)苯-1-硫代苯甲酰胺
• 中文别名: 2-(三氟甲基)苯-1-硫代甲酰胺
• 英文名称: 2-(trifluoromethyl)benzothioamide
• 英文别名: 2-(Trifluoromethyl)thiobenzamide；2-(trifluoromethyl)benzenecarbothioamide
• CAS: 886496-67-9
• 化学式: C₈H₆F₃NS
• 分子量: 205.204
• InChiKey: MBSSSIMORFRLOK-UHFFFAOYSA-N

物化性质

• 熔点：
  75-77℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  58.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  2-(三氟甲基)苯-1-硫代苯甲酰胺 在 sodium hydroxide 、 氯化亚砜 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 46.5h， 生成 2-Methyl-2-{4-[({4-methyl-2-[2-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}formamido)methyl]phenoxy}propanoic acid
  参考文献：
  名称：

  Substituted 2-[(4-Aminomethyl)phenoxy]-2-methylpropionic Acid PPARα Agonists. 1. Discovery of a Novel Series of Potent HDLc Raising Agents

  摘要：

  The peroxisome proliferator activated receptors PPAR alpha, PPAR gamma, and PPAR delta are ligand-activated transcription factors that play a key role in lipid homeostasis. The fibrates raise circulating levels of high-density lipoprotein cholesterol and lower levels of triglycerides in part through their activity as PPAR alpha agonists; however, the low potency and restricted selectivity of the fibrates may limit their efficacy, and it would be desirable to develop more potent and selective PPAR alpha agonists. Modification of the selective PPAR delta agonist 1 (GW501516) so as to incorporate the 2-aryl-2-methylpropionic acid group of the fibrates led to a marked shift in potency and selectivity toward PPAR alpha agonism. Optimization of the series gave 25a, which shows EC50 = 4 nM on PPAR alpha and at least 500-fold selectivity versus PPAR delta and PPAR gamma. Compound 25a (GW590735) has been progressed to clinical trials for the treatment of diseases of lipid imbalance.

  DOI：

  10.1021/jm058056x
• 作为产物：
  描述：

  2-三氟甲基苯腈 在 sodium hydrogen sulfide 、 magnesium chloride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以94%的产率得到2-(三氟甲基)苯-1-硫代苯甲酰胺
  参考文献：
  名称：

  含噻唑和恶唑部分的诺托普汀类似物的优化，构效关系和作用方式

  摘要：

  植物病害严重危害植物健康，很难控制。设计，合成和评估了一系列降钙素原类似物的抗病毒活性和杀真菌活性。这些化合物大多数显示出比病毒唑更高的抗病毒活性。具有优异抗病毒活性的化合物1d，1e和12a出现为新型抗病毒先导化合物，其中1e被选择用于进一步的抗病毒机制研究。机制研究结果表明，这些化合物可能通过聚集病毒颗粒来阻止其在植物中的移动，从而发挥抗病毒作用。进一步的杀真菌活性测试表明，降钙素原类似物具有广谱杀真菌活性。与商业杀菌剂多菌灵和百菌清相比，化合物2p和2f表现出更高的抗黑斑病菌的抗真菌活性。当前的研究为降钙素原类似物在植物保护中的应用奠定了基础。

  DOI：

  10.1021/acs.jafc.9b04093

文献信息

• Design, synthesis and Structure–activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes
  作者：Zheng Li、Qianqian Qiu、Xue Xu、Xuekun Wang、Lei Jiao、Xin Su、Miaobo Pan、Wenlong Huang、Hai Qian

  DOI：10.1016/j.ejmech.2016.02.040

  日期：2016.5

  The free fatty acid receptor 1 (FFA1/GPR40) has attracted interest as a novel target for the treatment of type 2 diabetes. Several series of FFA1 agonists including TAK-875, the most advanced compound terminated in phase III studies due to concerns about liver toxicity, have been hampered by relatively high molecular weight and lipophilicity. Aiming to develop potent FFA1 agonists with low risk of

  游离脂肪酸受体1（FFA1 / GPR40）作为治疗2型糖尿病的新靶标已引起人们的关注。相对较高的分子量和亲脂性阻碍了包括FAK1激动剂在内的数个系列的FFA1激动剂（由于对肝毒性的担忧而在III期研究中终止的最先进的化合物）。为了通过降低亲脂性来开发具有低肝毒性风险的有效FFA1激动剂，TAK-875的中间苯基被11个极性五元杂芳族化合物所取代。随后，对SAR的系统探索和分子建模的应用导致了化合物44的鉴定，它是一种出色的FFA1激动剂，在正常和2型糖尿病小鼠中均具有强大的降血糖作用，即使在两倍摩尔的TAK-875剂量下也具有低血糖风险和肝毒性。同时，指出了两个重要发现。首先，我们的噻唑系列中的甲基占据了一个小的疏水亚口袋，与TAK-875没有相互作用。此外，激动活性显示与噻唑核心和末端苯环之间的二面角具有良好的相关性。这些结果促进了对配体结合口袋的了解，并可能有助于设计更有希望的FFA1激动剂。
• [EN] FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS<br/>[FR] DERIVES HETEROCYCLIQUES FUSIONNES UTILISES EN TANT QUE MODULATEURS PPAR
  申请人：LILLY CO ELI

  公开号：WO2004063155A1

  公开（公告）日：2004-07-29

  The present invention is directed to compounds represented by the following structural formula, Formula I: wherein (a) X is selected from the group consisting of a single bond, O, S. S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of C, O, S, NH and a single bond; (d) E is C(R3) (R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamidek, sulfonamide and acylsulfonamide; (e) B is selected from the group consisting of S, O, C, and N; (f) Z is selected from the group consisting of N and C; with the proviso that when B is C then Z is N.

  本发明涉及由以下结构式I表示的化合物：其中（a）X选自单键、O、S、S（O）2和N组成的群；（b）U是脂肪链连接物；（c）Y选自C、O、S、NH和单键组成的群；（d）E是C（R3）（R4）A或A，其中（i）A选自羧基、四唑基、C1-C6烷基腈、羧酰胺、磺酰胺和酰基磺酰胺组成的群；（e）B选自S、O、C和N组成的群；（f）Z选自N和C组成的群；但当B为C时，则Z为N。
• HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR
  申请人：Uchida Hiroshi

  公开号：US20130079306A1

  公开（公告）日：2013-03-28

  A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27 Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.

  提供了一种新型杂环化合物或其盐，用于选择性地抑制p27Kip1的降解。该化合物或其盐由以下式（1）表示：其中A代表烷基、环烷基、芳基或杂环基，基团A可能有取代基；环B代表5至8成员的单环杂环环或包含该单环杂环环的缩合环，环B可能有取代基；环C代表芳香环，环C可能有取代基；L代表包含3至5个原子的主链的连接物，所述原子选自碳原子、氮原子、氧原子和硫原子组成的群，其中主链中的至少一个原子是选自氮原子、氧原子和硫原子组成的杂原子，连接物L可能有取代基；n为0或1。
• [EN] THIAZOLE OR OXAZOLE DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT OF CARDIOVASCULAR AND RELATED DISEASES<br/>[FR] DERIVES DE THIAZOLE OU D'OXAZOLE POUVANT ETRE UTILISES DANS LE TRAITEMENT DES MALADIES CARDIOVASCULAIRES ET APPARENTEES
  申请人：GLAXO GROUP LTD

  公开号：WO2002096894A1

  公开（公告）日：2002-12-05

  A compound of formula (1) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof: wherein R?1 and R2¿ are independently H or C¿1-3? alkyl or R?1 and R2¿ which are bonded to the same carbon atom may together with the carbon atom to which they are bonded form a 3-5 membered cycloalkyl ring; X¿1? represents O or S; Each R?3, R4, R8 and R9¿ independently represents H, halogen, -CH¿3? and OCH3; R?5¿ represents H or C¿1-6? alkyl or R?4 and R5¿ together form a 3-6 membered cycloalkyl ring. X¿2? represents NH, NCH3 or O; One of Y and Z is N, and the other is O or S; R?6¿ represents phenyl or pyridyl (wherein the N is in position 2 or 3) and is optionally substituted by one more halogen, CF¿3?, C1-6 straight or branched alkyl (optionally substituted by halogen), with the provision that when R?6¿ is pyridyl, the N is unsubstituted. R7 represents C¿1-6? alkyl, (optionally substituted by one or halogens), -C0-6 alkyl-5 membered heteroaryl C0-6 alkyl (O)n- phenyl, wherein n is 0 or 1, with the proviso that when R?1 and R2¿ are methyl, R?8 and R9¿ are H, R5 is H, then R7 cannot be CH¿3? or CF3.

  化合物的式子（1）及其药学上可接受的盐、溶剂化合物和可水解酯：其中R1和R2分别为H或C1-3烷基，或者R1和R2结合到同一个碳原子上，可以与它们结合的碳原子一起形成3-5成员的环烷基环；X1表示O或S；每个R3、R4、R8和R9分别表示H、卤素、-CH3和OCH3；R5表示H或C1-6烷基，或者R4和R5一起形成3-6成员的环烷基环。X2表示NH、NCH3或O；Y和Z中的一个是N，另一个是O或S；R6表示苯基或吡啶基（其中N在2或3位置），并且可以选择性地被一个或多个卤素、CF3、C1-6直链或支链烷基（可选择性地被卤素取代）取代，但是当R6是吡啶基时，N没有被取代。R7表示C1-6烷基（可选择性地被一个或多个卤素取代）、-C0-6烷基-5成员杂环烷基C0-6烷基（O）n-苯基，其中n为0或1，但是当R1和R2为甲基，R8和R9为H，R5为H时，R7不能是CH3或CF3。
• [EN] PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR ACTIVE DU PROLIFERATEUR DES PEROXYSOMES
  申请人：LILLY CO ELI

  公开号：WO2003072100A1

  公开（公告）日：2003-09-04

  The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I: (Formula I); wherein: (a) R5 is selected from the group consisting of (C1-C6) alkyl, (C1-C6) alkenyl, aryl (C0-C4) alkyl, aryloxy (C0-C4) alkyl, arylthio (C0-C4) alkyl, and further wherein when R5 is alkyl, R5 can optionally combine with W to form a 6 membered cycloheteroalkyl ring that is fused with the oxazole or thiazole ring to which the R5 group is attached; (b) R9 is selected from the group consisting of C1-C5 alkyl, C1-C5 alkenyl, and arylC0-C3alkyl; (c) T1 is selected from the group consisting of C and N; (d) W is selected from the group consisting of CH2, C(O)N(R21), N(R21), N(R21)CH2, O, OCH2, S, and SO2; and(e) X is selected from the group consisting of C, CH2C, and CCH2.

  本发明涉及以下结构式所表示的化合物及其药学上可接受的盐，公式I：（公式I）;其中：（a）R5选自（C1-C6）烷基，（C1-C6）烯基，芳基（C0-C4）烷基，芳氧基（C0-C4）烷基，芳硫基（C0-C4）烷基，进一步地，当R5是烷基时，R5可以选择与W结合形成一个6元环杂环烷基环，该环与R5基固定的噁唑或噻唑环融合；（b）R9选自C1-C5烷基，C1-C5烯基和芳基C0-C3烷基；（c）T1选自C和N的群；（d）W选自CH2，C（O）N（R21），N（R21），N（R21）CH2，O，OCH2，S和SO2的群；（e）X选自C，CH2C和CCH2的群。